Thursday, April 07, 2016

Nevada Energy Metals’ (TSXV: BFF.V; OTC: SSMLF; Frankfurt: A2AFBV), Advisory Board Member Malcolm Bell, Charged-up on Lithium!

Nevada Energy Metals’ (TSXV: BFF.V; OTC: SSMLF; Frankfurt: A2AFBV)Advisory Board Member Malcolm Bell, Charged-up on Lithium!


These days, investors in emerging lithium companies seem only to care about two things. How close is a property to a producing lithium operation (or basin with high lithium concentrations)? And, how many acres (hectares) is it? Look at Clayton Valley, Nevada, home to Albemarle Corp.’s Silver Peak lithium brine operation.

Conventional wisdom says to be as close to Silver Peak as possible, wielding as many acres as possible. However, newly appointed Technical Advisor Malcolm Bell of Nevada Energy Metals, Inc. (TSX-V: BFF)/ (OTC: SSMLF) / (Frankfurt: A2AFBV), believes there could be other Clayton Valley-like basins in the State. It’s not the zip code that counts most, but the geological setting and volcanic history.

Is it a certainty that Nevada will become a meaningful lithium suppler? No. But consider that an area of great promise for lithium-ion battery demand is the U.S. Department of Defense, (DOD). I mention it to support my view that, “security of supply” will be a crucial factor going forward. Will the DOD (indirectly) continue to rely on countries in South America and CHINA! for critical lithium-ion battery materials? 



If pricing remains stronger for longer, and demand continues to soar, the world will need more lithium, especially from safe, reliable jurisdictions. Companies like Nevada Energy Metals plan to be ready. As a project generator, the Company is well on its way in accumulating a robust portfolio of wholly-owned & JV properties. With Malcolm’s guidance, and the help of new hires (yet to be finalized), the team will have a lot on their plates. In fact, they already do, actively evaluating acquisitions and staking additional promising locations.

On March 22nd, Nevada Energy Metals appointed Mr. J. Malcolm Bell to the Advisory Board and as lead consultant for project acquisitions & land development opportunities.

Mr. Bell has over 45 years of resource industry experience either as principal, director, or senior officer of private & public companies. In 1980, he founded Hi-Tec Resource Management Ltd., a successful minerals exploration company. In 1986, he founded the International Investment & Business Opportunities Exposition, the first investment trade show company in Canada. 

In 1997, he co-founded British Canadian Mines Ltd., containing the largest privately held mineral exploration portfolio in Newfoundland; and subsequently completed a $13-million reverse merger on it. In 2002, he helped negotiate a $20-million merger between Olympic Resources Ltd & Whittier Energy Corp. Currently, Mr. Bell heads a private Vancouver-based consultancy that sources projects & capital for companies engaged in mining, renewable energy & technology ventures. 

I, Peter Epstein, CFA, MBA, caught up with Malcolm in the week ended April 1st to ask him a few questions. We spoke at length about his background and what he brings to the table. Mostly, he explained how nature has endowed Nevada with ideal conditions that, in select places, allow lithium to become concentrated in clays and brines.  

Your extensive experience in natural resources, including sourcing projects & capital, affords you opportunities to serve in advisory roles for many Nevada juniors. Why choose lithium, and why Nevada Energy Metals, Inc.? 

Nevada is an area of strong interest for me. At times it’s been for gold or copper, but now my focus is on lithium and its strategic importance. For months before joining the Technical Board, I was working closely with the Company on identifying and locking down lithium-bearing properties and staking ground. I helped them with the 100% acquisition of Teels Marsh West and with their option agreement on up to 60% of Alkali Lake.

 I’m very bullish on lithium demand and Nevada’s potential role in supplying it.



Regarding Nevada Energy Metals, I’m excited by the pace, the speed at which things are getting done. In addition to the two transactions mentioned, I helped successfully stake a very promising property in the San Emidio Desert basin. On top of that, the Company is already starting (next week) a phase 1 exploration program on Teels Marsh West

So, this is a company that wants to advance properties, not just sit on them. Regarding other lithium juniors, I think that I can add the most value here, by spearheading an aggressive property acquisition mandate. The Nevada Energy Metals has a lot of irons in the fire, the next few months should be a very active time for both the Company and me!  

You and Nevada Energy Metals are not alone in being bullish on lithium prospects in the State. What about the climate / geology of Nevada fostered the deposition of lithium in brines? 

That’s a great question. Dry desert-like climatic conditions and a favorable geological environment created conditions, over hundreds of thousands of years, that are today prospective for lithium in clays and lithium in brine deposits. There are four main reasons.  

Firstly, it’s generally recognized that undrained, or closed desert playa basins are the most prospective locations. Secondly, there should be a history of large-scale volcanic eruptions, contributing large volumes of volcanic ash, containing trace amounts of lithium into the basin. Thirdly, the basin should sit atop, or be in very close proximity to, a geothermal heat source and hot springs.

Finally, there needs to be (or have been) an inflow of lithium-bearing hot spring fluids into the closed basin over a very long period, to boost the lithium content of existing brines. Most important, the same heat source responsible for the hot springs, has to have created a hot water convection cycle. This hot water convection cycle is what ties it all together. Only a trace amount of lithium is in the hot water, BUT over thousands of years the convection cycle deposits lithium into the basin over and over and over again…. The continuous hot springs cycling allows lithium concentrations to build. 

Can you tell us about the staking of the San Emidio Desert basin?

Yes, the staking of 86 placer claims covering about 1,700 acres was announced last week. The property is about 60 miles (95 km) northeast of Reno, fairly close to where Tesla is building its giga-factory. The San Emidio Desert basin is an alkali playa environment being fed by lithium-bearing geothermal fluids. 



All of the criteria I described earlier is present at San Emidio. To be clear, this does not ensure that favorable brine concentrations will be found. But it shows it’s a promising target to explore and test for a commercial deposit. Given the limited exploration for lithium in Nevada to date, there certainly could be another Clayton Valley-like discovery. If the right conditions are in place, robust lithium brine deposits could be at large.

Can you please explain the initial phase of exploration at Teels Marsh West, and what you hope to accomplish?

Yes, we’re excited to start a surface exploration program on Teels Marsh West next week. The marsh covers roughly 2,000 acres (~810 hectares) in Mineral County. Lithium concentrations at Teels Marsh of up to 850 ppm were reported in sampling programs conducted by the US Geological Survey (OFR: 76-567).

The initial exploration phase consists of 20 shallow holes designed to collect fluid and sediment samples situated nearby a previously discovered thermal area. The area is on, and adjacent to, a range front fault system along the west side of the marsh. Close proximity to a geothermal heat source is believed to be a principal requirement for concentrating lithium in the brines at Clayton Valley.

Finding lithium concentrations is all fine and good, but the parts per million (ppm) are lower than the brines found in Argentina & Chile, why should anyone care about Nevada? 

I’m no expert in lithium fundamentals or pricing, but the only North American producing mine, Silver Peak, is thought to be concentrating brines with initial lithium values of 150ppm to 250ppm. That’s using the decades old technology / process of solar evaporation. Most geologists believe that closed basins in places like Clayton Valley would be able to produce average concentrations of at least 200ppm.

Right, 200ppm is less than South American lithium values, but Nevada is ground zero of several new processing technologies that have potential to be superior to harvesting brines in giant evaporation ponds. To be clear, these technologies are mostly in scale-up phase. Still, most lithium juniors around the world are several years from commercial production, leaving plenty of time for new technologies to catch up.  

Thank you Malcolm for your time and insightful answers to my questions. Good luck in your new role at Nevada Energy Metals.

For more information, about Nevada Energy Metals:

Trading Symbols: TSX-V: BFF  OTC Markets: SSMLF Frankfurt/Xetra: A2AFBV


(Article/interview of Malcolm Bell, Technical Advisor of Nevada Energy Metals, for InvestorIdeas.com)
Contact Info: Peter Epstein
845-304-7386

Disclosures: Readers are charged with conducting their own investment due diligence and recognize that small cap stocks can deliver a 100% loss of investment capital. The author or interviewer as the case may be, Peter Epstein, CFA, MBA, believes that he’s diligent and prudent in screening out companies that, for any reasons whatsoever, are unattractive investment opportunities. However, he cannot guarantee that his efforts will be successful. Readers understand that Mr. Epstein cannot be held accountable or responsible for the accuracy of opinions, facts, estimates, forecasts and assumptions conveyed herein or for investment actions taken by readers.

At the time this interview was published, Nevada Energy Metals was a sponsor of EpsteinResearch.com. Mr. Epstein owns stock in the Company. He is not a registered or licensed financial advisor. His article(s) on Nevada Energy Metals and other small cap companies should be considered very carefully in this context. Readers are urged to consult with their own financial advisors before making investment decisions. This company, and all small cap companies, are highly speculative, not suitable for all investors. 

Any commentary suggesting that a particular stock is, “under valued,” “over-sold,” a “compelling opportunity,” is “de-risked,” could be “re-rated,” or similar words and phrases, are not directed at any individual or group and do not constitute investment advice. Each individual and group must make their own determination regarding the suitability of any stock mentioned herein. Any comparisons between or among stocks are for illustrative purposes only and are not be taken as fact or relied upon. Nothing herein is to be considered explicitly or implicitly a part of full and proper due diligence.

This interview and does not constitute an offer or a solicitation of an offer for the purchase or sale of any shares or other securities of the companies referred to herein.  There are substantial risks associated with investing in development stage exploration companies.  Potential investors should seek advice from a qualified financial dealer prior to investing in any company referred to herein.  No securities commission or similar authority has in any way passed on any of the information contained in this interview.


This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published/created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Glaucoma Companies Aerie (Nasdaq:AERI), Glaukos (NYSE:GKOS), Q BioMed (OTCQB:QBIO), Inotek (Nasdaq:ITEK), NicOx SA (Paris: COX.PA) Approach a Devasting Disease with a Variety of Treatments

Glaucoma Companies Aerie (Nasdaq:AERI), Glaukos (NYSE:GKOS), Q BioMed (OTCQB:QBIO), Inotek (Nasdaq:ITEK), NicOx SA (Paris: COX.PA) Approach a Devasting Disease with  a Variety of Treatments

New York, NY; Pt, Roberts, WA - April 7, 2016- Investorideas.com, a digital global news source covering leading sectors including medical technology and biotech stocks releases the following report on Glaucoma and public companies currently involved in the treatment of the disease. Glaucoma is a group of eye diseases which result in damage to the eye’s optic nerve and left untreated will lead to vision loss and eventual blindness.

US Companies currently working on Glaucoma treatments include Q BioMed Inc, (QBIO), Aerie Pharmaceuticals (AERI), Glaukos Corporation (GKOS), Inotek (ITEK).

Internationally, NicOx SA (Paris: COX.PA) and Santen Pharmaceuticals Co. Ltd. (Tokyo:4536) are leading the way with research and development and treatment options for the disease.


Company News:
On March 28, Aerie Pharmaceuticals (NasdaqGM:AERI) issued a press release announcing the that dosing commenced of the first patients enrolled in Mercury 2, the Company’s second Phase 3 registration trial of Roclatan(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

The same day, Glaukos Corporation (NYSE:GKOS) announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its iStent® Trabecular Micro-Bypass Stent for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients diagnosed with mild to moderate open-angle glaucoma who are currently treated with ocular hypotensive medication. The iStent is the first-ever ab interno Micro-Invasive Glaucoma Surgery (MIGS) device approved for use in Japan.



Q BioMed Inc, (OTCQB:QBIO) expanded on the company’s Corporate Update with a Q&A with Investorideas.com and a video interview with StockNewsNow was also released.

In both interviews, President Denis Corin included the Mannin Research Inc. license agreement and the glaucoma eye drop treatment being developed by Dr. Susan Quaggin.  Mannin Research’s (Mannin) Glaucoma therapeutic is a first-in-class therapeutic designed to treat Primary Open-Angle Glaucoma. It is based on the research by Dr. Susan Quaggin, Director of the Feinberg Cardiovascular Research Institute and Chief of the Division of Nephrology and Hypertension at Northwestern University. The MAN-01 therapeutic is an important molecule in the context of new pharmaceuticals that can treat Glaucoma. Mannin’s therapeutic will address increased intraocular pressure in the eye by acting on a vessel in the eye called the Schlemm’s Canal, which is a main drainage path for the eye. Mannin is currently in the pre-clinical phase. Optimizing the molecule, the aim is to use it in the clinic in late 2017/early 2018.

In early March, Inotech Pharmaceutical Corporation (NasdaqGM: ITEK) announced that it had strengthened the Patent Estate for its lead drug candidate Trabodenoson, an investigational agent currently in pivotal Phase 3 clinical trials for the treatment of glaucoma.

In late February, NicOx SA (Paris: COX.PA) provided a corporate update which included a report on its US FDA review for an IOP (intraocular pressure) lowering singe-agent eye drop for patients with open-angle glaucoma

Santen Pharmaceuticals Co. Ltd. (Tokyo:4536.T; OTC: SNPHY) is focused on corneal disorders that lack effective treatment options and on glaucoma and retinal disorders that are increasing in prevalence due to the aging of society.

Novartis AG (NYSE:NVS) subsidiary Alcon, the global leader in eye care and a division of Novartis released news in February of 2016 announcing that it had entered into an agreement to acquire Transcend Medical, Inc., a privately-held, US-based company focused on developing minimally-invasive surgical devices to treat glaucoma.

Pfizer Inc’s (NYSE:PFE) Ophthalmology Unit indicates that it is interested in “establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers” in a number of ophthalmological areas including glaucoma.

Acadia Pharmaceuticals Inc.’s (NasdaqGS:ACAD) Muscarinic Program have discovered small-molecule product candidates for the treatment of glaucoma. Using a proprietary discovery platform, they identified a subtype of the muscarinic receptors that controls intraocular pressure and discovered lead compounds that selectively activate this target. 


The Market Outlook:
The global glaucoma surgical devices market is expected to reach USD 3.11 billion by 2020, growing at a CAGR of close to 41%, according to Technavio’s latest report.

TechNavio's analysts forecast the Global Glaucoma Therapeutics market will grow at a CAGR of 2.53 percent over the period 2013-2018.

TechNavio's analysts forecast the Global Glaucoma Devices market to grow at a CAGR of 20.72 percent over the period 2013-2018.



About Q BioMed Inc. (OTCQB:QBIO):
Q BioMed Inc. ("Q") is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

About Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI):
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daiIy IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma and ocular hypertension. It is expected that the NDA filing for Rhopressa (netarsudil ophthalmic solution) 0.02% will take place in the third quarter of 2016. The second product candidate, Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of Rhopressa and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a Roclatan NDA filing is expected to take place in the second half of 2017. In addition, Aerie is further building its pipeline, including through research collaborations with GrayBug, Inc. and Ramot at Tel Aviv University.  http://www.aeriepharma.com/

About Glaukos (NYSE:GKOS):
Glaukos is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent® its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. http://www.glaukos.com/

About Inotek Pharmaceuticals Corp. (NasdaqGM:ITEK):
Inotek  is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company's lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development Trabodenoson was developed in Inotek's laboratories and is designed to restore the eye's natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. http://www.inotekpharma.com/

About NicOx SA (Paris: COX.PA):
NicOx is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, Nicox is building a diversified portfolio of ophthalmic products that can help people enhance their sight. Nicox's advanced pipeline features latanoprostene bunod for the lowering of intra-ocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, and for which a New Drug Application (NDA) was submitted to the FDA by the Company's licensee Valeant. The Company's pipeline also features AC-170, a pre-NDA candidate for the treatment of ocular itching associated with allergic conjunctivitis, as well as two pre-MAA candidates in Europe: AzaSite® for bacterial conjunctivitis and BromSite(TM) for pain and inflammation after cataract surgery. Beyond these late-stage candidates, Nicox is developing a pipeline of next generation ophthalmology-focused candidates which utilize its proprietary nitric oxide (NO)-donating research platform. The Group has operations in Europe and the United States.
About Investorideas.com - Big Ideas for Global Investors
InvestorIdeas.com - digital media global news source, PR and social media in leading sectors.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for free news alerts at Investorideas.com
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: QBIO has retained investorideas.com for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com
800 665 0411


Wednesday, April 06, 2016

Mining in Mexico; Video Interview with President & CEO of SilverCrest Metals Inc (TSXV: SIL.V)

Mining in Mexico; Video Interview with President & CEO of SilverCrest Metals Inc (TSXV: SIL.V)



Vancouver BC, Point Roberts WA – April 6, 2016- Investorideas.com, a digital global news source covering leading sectors including mining stocks issues a  video interview  with N. Eric Fier, CPG, P. Eng and President , CEO, Director of SilverCrest Metals (TSXV: SIL.V; OTC: SVCMF).

Eric talks about their focus on Mexico properties in both past and current ventures, SilverCrest Mines Inc and SilverCrest Metals and gives insight on why Mexico is a recipe for success for his team.  He also discusses the recent progress and updates us on the Las Chispas Project, located in Sonora, Mexico.




Investorideas.com video channel on YouTube: https://www.youtube.com/c/Investorideas


About SilverCrest Metals Inc. (TSXV: SIL.V; OTC: SVCMF) http://www.silvercrestmetals.com
SilverCrest Metals Inc.is a Canadian precious metals exploration company headquartered in Vancouver, BC , that is focused on new discoveries, value-added acquisitions and targeting production in Mexico's historic precious metal districts. The Company is led by a proven management team in all aspects of the precious metal mining sector, including the pioneering of a responsible "phased approach" business model taking projects from discovery, finance, on time and on budget construction, and production with subsequent increased value to shareholders.

About Investorideas.com - Big Ideas for Global Investors
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also recently expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com http://www.investorideas.com/Resources/Newsletter.asp

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors including mining stocks

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: SilverCrest Metals is an annual publishing client of Investorideas.com, publishing news, video and social media.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com

800 665 0411

Tuesday, April 05, 2016

Biotech: Q BioMed Inc (OTCQB: QBIO) Featured in April Issue of PharmaVOICE Magazine

Q BioMed Inc (OTCQB: QBIO) Featured in April Issue of PharmaVOICE Magazine

Getting Past the "Pharma Bro"; How Smaller Biotechs Continue to Strive for the Well-Being of Patients



NEW YORK - April 5, 2016 (Investorideas.com Newswire) Q BioMed Inc. (OTC: QBIO), a biotechnology acceleration company reports the Company's CEO was featured in an interview in the April issue of PharmaVOICE magazine.

PharmaVOICE magazine, reaching more than 41,000 BPA-qualified life-sciences executives, is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry.

CEO, Denis Corin talks to PharmaVOICE magazine about Martin Shkreli's actions, drug prices and how he and his company are approaching the issues facing biotech innovators now and in the future.

Excerpt:
PV: Martin Shkreli's decision to increase the price of an inexpensive drug from $13.50 to $750 created a media uproar, reigniting negative attitudes toward the life-sciences industry. Is there anything positive that can come from this?

Corin: It's created a talking point, and it's provided more focus on the pharmaceutical industry and biotechnology to a degree. His approach and his attitude is just not consistent with the majority of people in pharma development and certainly not true of the younger, smaller biotech companies that are truly the innovators and the driving force behind a lot of new drug creation. This attitude is not reflective of the way many of us do things or the reasons why we do what we do.

Quite candidly, in the smaller-cap biotech space, companies are being run on shoestring budgets, and we're out there every day raising dollars wherever we can to develop these assets.

The way Shkreli's positioned this - gouging people on this one particular drug - is not representative of what's going on in the biotech innovation space. Every biotech CEO has to have some kind of philanthropy or philanthropic outlook on life when it comes to what he or she is doing. We have to be doing it for the ultimate good of the patients and their families and if we can do that, all things will fall into place and the company will do well. There will be ample profit for the shareholders and enough money to feed back into innovation and drug development.



About Q BioMed Inc.
Q BioMed Inc. ”Q“ is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

Forward-Looking Statements:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:
Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435 

Visit this Company: http://www.qbiomed.com

More info on QBIO at Investorideas.com: http://www.investorideas.com/CO/QBIO/

Sign up for the free investor news and stock alerts:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: QBIO has retained investorideas.com for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.







Technology: Gopher Protocol Inc. (OTC:GOPH) and Partner Commence Development, Issue Statement of Work and Complete FCC Survey for Guardian Global Tracking Device

Gopher Protocol Inc. (OTC:GOPH) and Partner Commence Development, Issue Statement of Work and Complete FCC Survey for Guardian Global Tracking Device

Guardian Patch can be affixed to any object, mobile or static, in order to track its location anywhere on earth



San Diego, California, April 5, 2016 – Gopher Protocol Inc. (OTC: GOPH) (“Gopher” and the "Company”), a development-stage Company developing a real-time, heuristic based, mobile technology, and its partner, Guardian Patch, LLC, announced that, in connection with the GopherInsight™ licensed technology, they have completed the Statement Of Work (SOW) for the FCC survey to deploy their Guardian Global Tracking Device within the continental U.S. and that they have also completed their transmitters/transceivers modules feasibility research.

Guardian Patch is an electronic circuit including a proprietary microchip technology that is within a sticky patch package. Guardian Patch can be affixed to any object, mobile or static, in order to track its location anywhere on earth.

Because the Guardian tracking system uses in part a synthetic radio frequency transmission for data, it is required to comply with various Federal Communications Commission (FCC) regulations relevant to the system, which the Company is complying with.
    

The Guardian Patch electronic circuit communicates with other similar working patches via a separate, secured, and private network. Upon affixing Guardian Patch on an object, the circuit is turned on, after which the electronic circuit regularly transmits an identification signal in order to identify the device’s geographical location worldwide in preset time intervals. Guardian Patch works in conjunction with a software application to provide tracking function operations via map and on-Earth coordinates. The system includes its own power source. Guardian Patch will also perform an emergency feature!  Users will be able to register the Patch ID on mobile apps of selected relatives and friends.  In the event of an emergency situation, one would simply peel Guardian Patch off. Upon removing Guardian Patch, it operates in a constant transmission mode, sending emergency signals. Guardian Patch also alerts the user's friends and family about the user's location.  No GPS or conventional network is needed.


The transmitters/transceivers modules feasibility research yielded a determination that the design and implementation of the Guardian Patch system and the carrier frequency selection comply with FCC regulations . The carrier frequency selection was achieved through the licensing of a certain frequency band providing an optimal performance. A set of working frequencies were evaluated considering performance, power consumption aspects, interference avoidance and FCC compliances. 

The FCC regulates the limits of potential harmful interference to licensed transmitters due to low power unlicensed transmitters. The Guardian Patch system consists of advanced security protocols in order to maintain the global, private, fully-secured network. In addition, the Guardian Patch device needs to perform communication tasks across the globe providing breakthrough tracking features. Utilizing their robust intellectual property portfolio and experienced personnel, the Company and its partner, Guardian Patch, LLC (collectively, "GPLLC") , successfully completed thorough research which involved security, performance and FCC regulations compliance. Based on this research a set of particular frequencies were chosen to be used by the GPLLC. 

To view Guardian Patch's technical features, download the following link: http://www.gatpatch.com/docs/Guardian-3-3-2016.pdf

A new consumer and product website was launched last week at http://www.guardianpatch.com/The product will be presented for pre-sale, utilizing social media on top of customary distributing channels for the product, for which further announcements will be provided.


About Gopher Protocol Inc.
Gopher Protocol Inc. (“Gopher” and the "Company") (OTC: GOPH) (http://gopherprotocol.com/) is Development-stage Company that is developing a real-time, heuristic based, mobile technology, per license agreement it holds. Upon development, the technology will consist of a smart microchip, mobile application software and supporting software that run on a server. The system contemplates the creation of a global network, worldwide. Gopher believes this will be the first system that is developed using a human, heuristic based analysis engine. Since the core of the system will be its advanced microchip that will be able to be installed any mobile device, worldwide, Gopher expects that this will result in an internal, private network between all mobile devices utilizing the device by providing mobile technology for computing power enhancement, advanced mobile database management/sharing, and additional mobile features.

Contact:
Dr. Dan Rittman, CTO
Gopher Protocol Inc.
888-685-7336


Visit this company: http://gopherprotocol.com/

More info on GOPH at Investorideas.com Visit: http://www.investorideas.com/CO/GOPH/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GOPH is a PR , social media and publishing client and compensates Investorideas.com ( three months effective April 4, 2016- three thousand five hundred per month )

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Monday, April 04, 2016

Mining Stocks Video Release: Clip of Upcoming Interview with SilverCrest Metals Inc (TSXV: SIL.V)


Vancouver BC, Point Roberts WA – April 4, 2016- Investorideas.com, a digital global news source covering leading sectors including mining stocks issues a video promo clip of the upcoming full interview with SilverCrest Metals Inc (TSXV: SIL.V). This week we interview N. Eric Fier, CPG, P.Eng and President /CEO, Director of SilverCrest Metals.

In this clip leading up to the full interview Eric talks about the ups, downs and the cycles of the mining sector and says “I like to make money in a good or bad market and that’s part of our success. We are survivors and everyone at PDAC this year should be applauded for being survivors in this market and we look for a rise in the tide coming.”




See the full interview later this week on Investorideas.com video channel on YouTube: https://www.youtube.com/c/Investorideas

About SilverCrest Metals Inc. (TSXV: SIL.V; OTC: SVCMF) http://www.silvercrestmetals.com
SilverCrest Metals Inc.is a Canadian precious metals exploration company headquartered in Vancouver, BC , that is focused on new discoveries, value-added acquisitions and targeting production in Mexico's historic precious metal districts. The Company is led by a proven management team in all aspects of the precious metal mining sector, including the pioneering of a responsible "phased approach" business model taking projects from discovery, finance, on time and on budget construction, and production with subsequent increased value to shareholders.

About Investorideas.com - Big Ideas for Global Investors
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also recently expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas


Sign up for free news alerts at Investorideas.com http://www.investorideas.com/Resources/Newsletter.asp

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors including mining stocks

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: SilverCrest Metals is an annual publishing client of Investorideas.com, publishing news, video and social media.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com

800 665 0411